Long Focus Capital Management LLC Acquires 781,808 Shares of Aura Biosciences, Inc. $AURA

Key Points

• Long Focus Capital Management LLC increased its stake in Aura Biosciences by 30.8%, acquiring an additional 781,808 shares, bringing its total holdings to 3,319,582 shares valued at approximately $19.45 million.
• Aura Biosciences stock has shown variability, with a 52-week low of $4.34 and a high of $12.38, and currently has a market cap of $388.87 million.
• Analysts maintain a generally favorable outlook on Aura Biosciences, with a consensus rating of "Buy" and a target price averaging $22.00 per share.

Long Focus Capital Management LLC boosted its stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 30.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,319,582 shares of the company's stock after purchasing an additional 781,808 shares during the quarter. Long Focus Capital Management LLC owned about 6.61% of Aura Biosciences worth $19,453,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BNP Paribas Financial Markets acquired a new position in Aura Biosciences in the fourth quarter valued at about $50,000. GAMMA Investing LLC raised its stake in Aura Biosciences by 5,766.9% during the first quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock worth $57,000 after acquiring an additional 9,573 shares in the last quarter. ProShare Advisors LLC acquired a new position in Aura Biosciences during the fourth quarter worth about $127,000. Harbor Capital Advisors Inc. acquired a new position in Aura Biosciences during the first quarter worth about $151,000. Finally, Wells Fargo & Company MN raised its stake in Aura Biosciences by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 27,623 shares of the company's stock worth $227,000 after acquiring an additional 5,930 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on AURA shares. Zacks Research raised Aura Biosciences from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Aura Biosciences in a research note on Wednesday, August 13th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $19.00 price objective on shares of Aura Biosciences in a research note on Friday, May 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Aura Biosciences presently has a consensus rating of "Buy" and a consensus target price of $22.00.

Insider Activity

In other Aura Biosciences news, SVP Amy Elazzouzi sold 7,722 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $6.70, for a total transaction of $51,737.40. Following the transaction, the senior vice president directly owned 86,558 shares in the company, valued at approximately $579,938.60. This represents a 8.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.30% of the company's stock.

Aura Biosciences Trading Up 0.5%

AURA stock traded up $0.03 during trading on Wednesday, hitting $6.34. The company had a trading volume of 122,851 shares, compared to its average volume of 214,330. The business has a 50-day moving average of $6.63 and a 200-day moving average of $6.40. Aura Biosciences, Inc. has a one year low of $4.34 and a one year high of $12.38. The stock has a market cap of $393.84 million, a PE ratio of -3.23 and a beta of 0.45.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Research analysts forecast that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.